Novavax: 'We still expect to enjoy the advantage of being the first RSV vaccine'
Gaithersburg-based Novavax executives still believe their company is leading the race to produce a vaccine against respiratory syncytial virus, or RSV, they told investors during a Monday earnings call.
Novavax (NASDAQ: NVAX) recently opened a phase 2 clinical trial to begin retesting its previous lead vaccine candidate for elderly patients after suffering a devastating failed phase 3 clinical trial in September. RSV is the most common cause of pneumonia and inflammation of the small airways in…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Tina Reed Source Type: news
More News: Biotechnology | Clinical Trials | Health Management | Pneomococcal Vaccine | Pneumonia | Respiratory Medicine | Vaccines